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COX = cyclooxygenase; ERK = extracellular signal-regulated MAP kinase; IC50 = inhibitory concentration 50%; IFN = interferon; IκBα = inhibitor of
κB alpha; IKK2 = IkappaB kinase beta; IL = interleukin; MAP = mitogen-activated protein; MHC = major histocompatibility complex; MKK = MAP
kinase kinase; NF = nuclear factor; RA = rheumatoid arthritis; SCID = severe combined immunodeficient; SNP = single nucleotide polymorphism;
Th = T helper cell; TNF = tumour necrosis factor.
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Introduction
Some 200 delegates convened for the 22nd annual Euro-
pean update on progress in research into the rheumatic
diseases. This meeting has always been popular, since it
brings together rheumatologists and basic scientists who
share a common interest in exploring disease pathogen-
esis and identifying new therapeutic targets. It also pro-
vides opportunities for young investigators to present their
unpublished work. This year was no exception, with nine
plenary sessions ranging from technologies and genomics
to cytokines and signal transduction pathways. In striving
to meet its objectives, around 40% of all posters pre-
sented at the meeting were also discussed through oral
presentations. Delegates were also treated to an array of
outstanding research expertise based locally.
Review
Pathology and pathogenesis
Evolving concepts of autoimmune disease propose that
the overwhelming default response of the immune system
of the nonsusceptible host is immune regulation. Accord-
ing to this model we are all exposed to ‘danger signals’
(P Matzinger, Bethesda, MD, USA), but the key to under-
standing why some individuals are disease susceptible
lies in the mechanisms whereby the immune response is
not only initiated, but also perpetuated.
In her keynote address, P Matzinger proposed an
approach to understanding the different mechanisms for
the development of rheumatic autoimmune diseases.
Diseases were used to illustrate each of five possible
mechanisms for autoimmunity and chronic inflammation: (i)
infection, illustrated by Lyme disease; (ii) molecular
mimicry, illustrated by rheumatic fever and possible flares
of inflammatory arthritis; (iii) ‘bad death’ as a result of
mutations in ‘clean-up’ genes, illustrated by systemic lupus
erythematosus; (iv) immune impressionism where injury or
insult leads to immune epiphenomena, such as the pro-
duction of autoantibodies to nucleolar antigens, illustrated
by scleroderma; and (v) ‘wrong class of immune response’,
a switch from a Th2 response to a Th1 response, illus-
trated by type I diabetes and multiple sclerosis (examples
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of a ‘correct class of immune response’ being IgA
responses in the gut, and anterior chamber of the eye
driven by transforming growth factor beta and vasoactive
intestinal peptide).
Antigen presentation and lymphocyte activation
An important component of this ‘danger’ theory is the pro-
cessing of autoantigens by professional antigen-present-
ing cells and the presentation of specific peptides to
T cells. This process is poorly understood in autoimmune
disease, but working models propose that post-transla-
tional modifications of self antigen might provide one
mechanism of generating neoepitopes not encountered by
T cells during maturation in the thymus.
Coeliac disease is not strictly an autoimmune disease,
since there is an increased precursor frequency of T cells
specific for peptides derived from the dietary wheat
protein gliadin. But what is interesting about immuno-
dominant gliadin epitopes is that tissue transglutaminase,
which is also the target of autoantibodies in patients, plays
a role in the deamidation of glutamine residues (F Koning,
Leiden, The Netherlands). A modification from glutamine
to glutamic acid by transglutaminase requires a specific
motif QXPQX, where X may be a hydrophobic residue.
Database searches for such motifs reveal hits in gluten,
barley and rye (which are not tolerated by coeliac
patients), but not in oats (which is tolerated). This raises
the possibility that the generation of modified epitopes at
sites of inflammation may be tissue specific.
Another good example is the expression of peptidylarginine
deiminase type 2 by monocyte-derived macrophages,
which leads to the citrullination of potential synovial target
antigens such as fibrin and vimentin. These are good exam-
ples of neo-epitope targets of the autoimmune B-cell
response in rheumatoid arthritis (RA) and are thought to be
generated in the synovial joint (E Vossenaar, Nijmegen, The
Netherlands).
Members of the tumour necrosis factor (TNF)/TNF-recep-
tor superfamily of ligands and receptors have received
much attention recently. The role of RANKL/RANK in
osteoclastogenesis and the BLyS/BAFF-R system in
B-cell autoimmunity are two such examples.
Insight into the function of another family pair,
CD27L(CD70) and CD27, has come from a detailed
analysis of CD70 transgenic and CD27 mutant mice
(R van Lier, Amsterdam, The Netherlands), the transgenic
mouse being the more revealing. While delayed type
hypersensitivity responses are depressed in CD27–/–
mice, CD70 enhanced delayed type hypersensitivity and
cytotoxic T-lymphocyte responses when expressed under
the CD19 promoter, as demonstrated by MHC class I
tetramer staining. Strikingly, CD27–/– T cells expressed
the activation markers CD44hi CD62Llo in the absence of
antigenic stimulation in vitro and produced more IFN-γ. A
decreased life span through infection was reflected in
reduced total lymph node and thymic cellularity, suggest-
ing that these T cells, many of which are Ki67+, are termi-
nally differentiated and senescent as a consequence of
chronic antigenic stimulation. It is now well established
that such cells have, as a consequence of their replicative
history, shortened telomeres. They do not proliferate well
and, historically, this has made senescent T cells difficult
to study. This problem has now been resolved in part,
since replication is restored, and much of the function is
retained by overexpressing hTERT (H Spits, Amsterdam,
The Netherlands). This approach does not, however,
appear to work in B cells.
Inflammation
The expanding IL-1 superfamily received a good airing at
the Workshop. The importance of regulation of IL-1 in vivo
is now well established, based in part on the phenotype of
mice deficient for the naturally occurring IL-1 inhibitor, IL-
1ra (G Duff, Sheffield, UK).
The disease phenotypes, which are striking, depend on
the background strain. In outbred Swiss albino mice, the
predominant phenotype is that of a medium to large vessel
vasculitis; survival is decreased to a substantial extent
largely through myocardial infarction and aneurysm forma-
tion. The same mutation leads to a destructive polyarthritis
in Balb/c mice with 100% penetrance, with arterial
disease being insignificant, while in C57BL/6 mice there
is no vessel inflammation and the penetrance of arthritis is
less pronounced.
IL-18 presents itself as a promising therapeutic target in
inflammatory arthritis. The effects of anti-IL-18 antibodies,
the IL-18 binding protein or the IL-18–/– genotype on the
incidence and severity of collagen-induced arthritis cer-
tainly supports this idea (I McInnes, Glasgow, UK). IL-18 is
expressed in inflamed synovium in RA, and while in vitro
the IL-18Rα chain has been shown to be expressed on a
subset of Th1 cells, the main target of action appears to
be the macrophage. Indeed, IL-18 blockade suppresses
TNF production by ~50% in cultures of dissociated
synovial cells. Unlike IL-1, however, IL-18 processing from
pro-IL-18 appears to be caspase (e.g. IL-1 converting
enzyme) independent. Studies using cells from elastase-
deficient mice and cathepsin-G-deficient mice suggest
that elastase may be important for IL-18 processing, at
least in neutrophils.
IL-17 and its role in inflammatory joint disease has
received more attention recently. However, it is distinctive
in that its expression can be detected in synovial T cells,
unlike many T-cell-derived cytokines. The immunobiology
of IL-17 is IL-1-like in that it induces TNF and IL-1 expres-278
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sion, but it also has chemotactic activity for neutrophils. Its
expression has been studied in association with the pres-
ence of erosions in inflamed joints, and the fact that it
upregulates RANKL expression and secretion suggests a
possible role in osteoclastogenesis (E Lubberts,
Nijmegen, The Netherlands). Consistent with this is the
finding that overexpression of IL-17 in collagen-induced
arthritis by adenoviral transgenesis promotes cartilage
destruction and erosion of bone, effects that may be IL-1
independent. In preliminary studies, the effects of IL-17
blockade seemed less striking than those observed follow-
ing attenuation of activity of other IL-1 family members.
Diagnostics and prognostics
There seems little doubt that technology has already influ-
enced our capacity to genotype and serotype patients
with arthritis and other inflammatory disorders. In the next
few years, profiling may become routine. With this technol-
ogy comes information overload, and physicians will need
to be prepared for this. The techniques available to us are
expanding, as too are the hardware and software to help
us cope. The key lies in pattern recognition, since cohesive
patterns of gene regulation determined by cluster analysis,
for example, can provide important clues as to cellular
processes, signal transduction pathways and gene trans-
activation by families of transcription factors in the context
of disease (C Reich, Boston, MA, USA). To this end, our
own prior knowledge must be channelled in ways that will
facilitate the process, rather than hinder it.
Exploring the genetic basis of osteoarthritis is a case in
point, since the most consistent candidate genes that turn
up in association studies include COL2A1, aggrecan and
insulin growth factor-1 (E Slagboom, Leiden, The Nether-
lands). These may seem obvious candidates, but the
choice may be biased. Perhaps the biggest surprise over
recent years is the significant genetic contribution to the
disease, with computations of up to 78% for heritability.
The results depend on the phenotype of probands. Never-
theless, the long arm of chromosome 2 has thrown up
some potentially exciting genetic intervals as a result of
genome-wide scans, with LOD scores ranging from 2.5 to
5.3 (E Slagboom).
Recent data suggest that, across the chromosome,
recombination rates are highly variable. This in itself is
worthy of more detailed study. The implications are excit-
ing, because they suggest that analysis of haplotypes
across large regions of chromosomes may provide a
meaningful approach to exploring genetic variation and
susceptibility to disease. This was elegantly illustrated with
cytokine gene polymorphisms, using as a prototype haplo-
types of the IL-1 gene family based on groups of single
nucleotide polymorphisms (SNPs) (G Duff, Sheffield, UK).
IL-1A, IL-1B and IL-1RN are just three of a cluster of at
least 14 genes on chromosome 2 where up to 100 SNPs
appear to be inherited in a nonrandom fashion (linkage
disequilibrium). For example, haplotyping according to
IL-1A, IL-1B and IL-1RN [e.g. IL-1A(–889), IL-1B(–511),
IL-1B(+3953), IL-1RN intron 2 variable nucleotide tandem
repeats] SNPs reveals one IL-1 genotypic pattern with an
odds ratio of 4.0 for cardiovascular disease (comparable
with that of smoking).
Combined with cholesterol levels, predictive values are
further enhanced. This haplotype pattern also confers
threefold to fourfold increases in IL-1β production in
response to lipopolysaccharide stimulation. One IL-1B
haplotype has been identified in patients with RA. More
exciting are the recent pharmacogenotyping analyses of
patients treated with IL-1RA, since it turns out that
patients carrying the IL-1A*2-containing haplotype are
more likely to respond to treatment (63.4%) than non-
carriers (26.3%). A similar approach would be valuable for
assessing responses to TNF blockade, but there are major
economic implications. For example, this approach pre-
dicts that physicians and pharmaceutical industries alike
face further challenges in the future when confronted with
very low frequencies of responder haplotypes within the
disease population. Regardless of this, the prospect for
genotype-directed therapy, stratified to SNP haplotypes, is
an exciting one.
Reverse genomics is a term now being used for autoanti-
body profiling, a technology where a large number of
peptide or protein antigens (200 pg antigen in a 1 nl
volume) are ‘arrayed’ onto poly-L-lysine-coated glass
slides, probed with sera from patients and are detected
with Cy3-labelled anti-human IgG (W Robinson, PJ Utz,
Stanford, CA, USA). This has the major advantage of
immediate identification and can also be used for more
precise epitope mapping, an approach that has already
been validated in mouse models of autoimmunity. For
example, the arthritis chip carries proteins such as colla-
gen type II, HCgp-39, vimentin and other citrullinated anti-
gens, and ‘mixed connective tissue disease’ and ‘myelin’
chips have also been generated. This large-scale
serotypic profiling has huge potential for both diagnostics
and prognostics in a broad range of diseases.
Therapeutic targets
The arena of target identification and validation has always
been a hot one. For example, there has been considerable
progress in the identification of anatomical ‘post codes’
that direct leukocytes to specific tissues such as the
inflamed synovial joint. The laboratory of Pitzalis and col-
leagues, London, UK, have combined phage display tech-
nology and in vivo ‘panning’ techniques using
human–SCID chimeras to identify peptide ligands that
may selectively target synovial tissue microvascular
endothelium. The elegance of this approach is in the in
vivo validation, since synthetic peptides based on phage279
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insert sequences can then be tested for their capacity to
bind and block leukocyte trafficking to synovial tissue, but
not to other organs (L Lee, London, UK). There seem to be
specific motifs, but whether these bind one integrin mole-
cule or integrin-like molecule or several distinct surface
receptors awaits further investigation.
Signal transduction pathways have for many years
seemed attractive candidates as therapeutic targets
based on the assumption that they might provide more
specificity and selectivity than the current approaches
cytokine blockade has to offer. Until the redundancy and
pathway overlaps have been comprehensively mapped
this will remain an assumption, but much emphasis has
been placed on targeting NF-κB, MAP kinase and their
upstream activators. There is increasing evidence for NF-
κB drive in inflamed RA synovium based on the anti-
inflammatory effects of expressing IκBα in dissociated
cultures of synoviocytes using adenovirus-based vectors
(M Feldmann, London, UK). The effects of NF-κB-inducing
kinase in promoting dendritic cell antigen-presenting func-
tion would also seem to suggest that targeting this
pathway may have effects that are not just confined to the
inflammatory response.
Consistent with this model are data demonstrating potent
disease-promoting and ameliorating effects of dominant-
active IKK2 and dominant-negative IKK2 when injected
into the knee in rat adjuvant arthritis (A Manning, St Louis,
MO, USA in collaboration with the Firestein Laboratory,
San Diego, CA, USA). A putative IKK2 small molecule
inhibitor has now been developed (SC-514) that has an
IC50 value of 10–20 µM following IL-1β stimulation, but
does not completely block IκBα degradation at 30 µM.
The effects of this agent in vivo are awaited with interest,
as are the effects on innate immunity.
SP600125, on the contrary, inhibits c-Jun N-terminal
kinase activity with an IC50 value of ~100 nM. Its speci-
ficity is suggested by the fact that p38 and ERK activity
cannot be inhibited at drug concentrations >30 µM. In
assays of T-cell activation and differentiation, SP600125
inhibited anti-CD3/anti-CD28-induced proliferation and
inhibited differentiation along the Th1 lineage.
The effects of p38 inhibition are currently under investiga-
tion, and several pharmaceutical companies have invested
heavily in developing specific inhibitors. Part of the reason
for this lies in the potent effects of this MAP kinase on
post-transcriptional regulation of inflammatory gene expres-
sion. This effect is particularly pronounced for genes that
carry reiterative AUUUA repeats in their 3′ untranslated
region, such as the COX2 and TNF-α genes (J Saklatvala,
London, UK). This has raised the possibility that the p38
pathway may act on RNA binding proteins, leading ulti-
mately to enhanced mRNA stability. This was shown for
COX2 mRNA using a Tetoff reporter system. The effects
can be blocked with the p38 inhibitor SB203580 or pro-
moted with dominant-active mutants of MKK6, which act
upstream of p38 (J Saklatvala). More intriguing is the
finding that the synthetic corticosteroid dexamethasone is
a potent inhibitor of this pathway, leading to destabilisation
of inflammatory gene mRNA species. A detailed analysis
revealed that dexamethasone at nanomolar concentrations
targets p38 directly, perhaps by upregulating the expres-
sion and/or activity of a p38 phosphatase. These studies
illustrate how detailed molecular analysis of the activities of
anti-inflammatory agents that have been tried and tested in
the clinic for almost half a century can provide considerable
insight into the inflammatory process.
Concluding remarks
Huge progress in the development of new technologies
permits us to explore pathways and disease processes on
a scale that would not have been possible 5 years ago.
One key challenge that must be overcome relates to infor-
mation overload, and the mechanisms whereby the signifi-
cant data can be dissected from the background noise.
Nevertheless, this meeting has demonstrated unambigu-
ously that such advances are already paying dividends in
furthering our understanding of mechanisms of disease
pathogenesis. In a convivial atmosphere, we have also
experienced first hand that this knowledge is already
being translated into the development of exciting new
therapeutic targets with a ‘tailor-made’ flavour.
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